Drugs With Semaglutide Linked to Deep Vein Thrombosis and Pulmonary Embolism
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active ingredient. Semaglutide is associated with a significantly increased risk of blood clots. Ozempic, Wegovy, and Rybelsus causing deep vein thrombosis (DVT) and pulmonary embolism (PE) as blood clots side effects is a drug safety issue that is not well-known. Rather, blood clots have been overshadowed by gastrointestinal and stomach problems linked to Ozempic, Wegovy, and Rybelsus, such as gastroparesis.
We are looking into possible drug injury lawsuits for patients who developed deep vein thrombosis (DVT) or pulmonary embolism (PE) due to these severe blood clots side effects of semaglutide weight-loss drugs Ozempic, Wegovy, and Rybelsus.
No Warnings About Blood Clots Side Effects
There are no warnings about an increased risk of blood clots side effects in the current drug labels for Ozempic, Wegovy, and Rybelsus. This failure to warn by Novo Nordisk (the pharmaceutical company responsible for Ozempic, Wegovy, and Rybelsus) is a drug safety issue for two reasons:
- A 2021 medical journal article reported that researchers found semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, increased the risk of deep vein thrombosis (DVT) by 266% in patients with type 2 diabetes.
- The blood clots side effects for Ozempic, Wegovy, and Rybelsus are particularly alarming since patients with type 2 diabetes who are also overweight already have an increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Those two reasons become more clear when taking into consideration this background information about semaglutide weight-loss drugs:
- The FDA approved Ozempic as a Type 2 diabetes treatment, such that Ozempic is being used “off-label” for weight loss;
- Likewise, Rybelsus was approved as Type 2 diabetes treatment so it, too, is being used “off-label” for weight loss; and,
- Only Wegovy was approved by the FDA as a treatment for adult obesity and “indicated” for weight loss, so it is not being used “off-label” for weight loss.
Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients hospitalized with deep vein thrombosis (DVT) or pulmonary embolism (PE) would be filed against Novo Nordisk for this failure to warn about the blood clots side effects of semaglutide. Those legal cases would not be filed against the patient’s doctor because there were no warnings about an increased risk of blood clots for Ozempic, Wegovy, and Rybelsus.
Free Case Evaluation for Blood Clots Side Effects of Ozempic, Wegovy, and Rybelsus
We encourage you to submit a Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible Ozempic, Wegovy, or Rybelsus drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Article About Ozempic, Wegovy, and Rybelsus Causing Blood Clots, DVT, PE
Semaglutide-Related Blood Clots Cases: Ozempic, Wegovy, and Rybelsus
We have been receiving reports of people diagnosed with deep vein thrombosis (DVT), pulmonary embolism (PE), portal vein thrombosis (PVT), and ischemic stroke possibly due to semaglutide-related blood clots. Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active ingredient.
Semaglutide-Related Blood Clots Cases: DVT and Pulmonary Embolism
Here are some reports of DVT and pulmonary embolism involving semaglutide drugs we have received in the past several months:
Ozempic – Deep vein thrombosis (DVT) and pulmonary embolism were diagnosed in a 66-year-old woman who had been using Ozempic for 2 months.
Ozempic – Pulmonary embolism (PE) and DVT were diagnosed in a 53-year-old man who had been using Ozempic for 1 year.
Ozempic – Blood clots in both lungs, which is a bilateral pulmonary embolism, were diagnosed in a 46-year-old woman who had been using Ozempic for 2 months.
Rybelsus – DVT was diagnosed in a 62-year-old woman who had been using Rybelsus for 1 month.
Semaglutide-Related Blood Clots Cases: Other Medical Conditions
Here are some reports of other blood clot conditions involving semaglutide drugs we have received in the past several months:
Ozempic – Blood clot in the portal vein, or portal vein thrombosis (PVT), was diagnosed in a 44-year-old woman who had been using Ozempic for 2 weeks.
Wegovy – Ischemic stroke was diagnosed in a 45-year-old man who had been using Wegovy for 3 months.
We are investigating possible Rybelsus, Wegovy, and Ozempic drug injury lawsuits for people diagnosed with deep vein thrombosis (DVT), pulmonary embolism (PE), portal vein thrombosis (PVT), ischemic stroke, or any other blood clot-related side effects.
Let us know if we can assist you or someone you know with a Wegovy, Rybelsus, or Ozempic blood clot case. One way to do this is to submit an online Case Evaluation Form.
[Read the article in full at source]Earlier articles about blood clots side effects of Ozempic, Wegovy, and Rybelsus:
- Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic
- Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects
Earlier articles about Ozempic, Wegovy, and Rybelsus by attorney Tom Lamb on the Side Effects Blog:
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
- Symptoms and Diagnosis of Weight-Loss Drugs Gastroparesis Side Effects for Ozempic, Rybelsus, Wegovy, and Trulicity
- Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study
- Ozempic Intestinal Blockage and Obstruction Cases Increasing
- Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
- Ozempic-Related Gastroparesis, Stomach Paralysis, Intestinal Blockages